235.041 Buprenorphine Access for Opioid Substance Use Disorder Treatment

235.041

Buprenorphine Access for Opioid Substance Use Disorder Treatment: The Texas Medical Association supports (1) state efforts to increase the reimbursement rate of buprenorphine to better reflect its actual cost and medication-assisted treatment overhead costs to physicians and (2) the elimination of preauthorization requirements for insured patients with opioid use disorders seeking buprenorphine treatment (Res. 415-A-19).

Last Updated On

June 20, 2019